Opinions Glenn Paradis, BA, CFA
Labopharm IncDDS.TOPAST TOP PICKApr 01, 2002
(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.
Glenn Paradis, BA, CFAUnknown
$5.80
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
DON'T BUY
WATCH
Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.
biotechnologypharmaceutical
DON'T BUY
Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.
biotechnologypharmaceutical
